about
Cholinergic imaging in dementia spectrum disordersProgressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment OptionsParkin-deficient mice are not a robust model of parkinsonism.Neuroimaging of brain changes associated with cognitive impairment in Parkinson's disease.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease.Decision-making cognition in neurodegenerative diseases.Occurrence of depression and anxiety prior to Parkinson's disease.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease.Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptomsNonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory studyEffect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving ratsFrequency and correlates of co-morbid psychosis and depression in Parkinson's disease.Animal models of the non-motor features of Parkinson's disease.Suicidal and death ideation in Parkinson's disease.Electroacupuncture Alleviates Depressive-Like Symptoms and Modulates BDNF Signaling in 6-Hydroxydopamine RatsEmerging analgesic drugs for Parkinson's disease.Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: a systematic review.Review of delirium in patients with Parkinson's disease.Parkinson's disease: genetics and beyond.Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy.Proanthocyanidin-rich fraction from Croton celtidifolius Baill confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson's disease.Problem solving therapy for the treatment of depression for a patient with Parkinson's disease and mild cognitive impairment: a case study.Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study.Immediate effects of physical therapy on gait disturbance and frontal assessment battery in Parkinson's disease.Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy.The ethics of deep brain stimulation (DBS).Patterns of psychological problems in Parkinson's disease.Depressive symptoms in Parkinson disease: degree of association and rate of agreement of clinician-based and self-report measures.Validity and reliability of the Geriatric Anxiety Inventory in Parkinson's disease.[Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease]
P2860
Q26764933-D3C35253-D81A-4346-B2AD-37036E490631Q28072101-E0D70BA6-99DE-4801-967C-A312813BBA1CQ28504677-0AD16A74-C981-406C-82AC-38408DF355E1Q30611520-B939F8B3-4175-4316-9993-AA0ADC6C3E92Q33260251-AB9E36EA-57A8-4E69-AF7E-FC42E5FCEDCCQ33967902-C0F55E1D-C589-430E-A9A2-3B9141089D94Q34147683-5F9CD518-21F9-4EAC-8B00-DC28FC085C37Q34238344-5F9B57C6-B964-4459-A7DB-6EF7AA652290Q34307633-E5F8B7A2-6B57-44B8-B19C-7EB5AB218303Q34417896-CEC9E610-4C84-4DF5-B1E4-F42761CE6010Q34638941-5F393960-17D5-4016-9B22-875ABB5B6270Q35028869-3EFEE252-E60F-4CCF-8D44-BE315B91690EQ35049086-98C0AFB4-8D38-40EC-AD5C-14B777A03E68Q36011226-1E058F2E-9B59-4FE3-982D-E621E9F68223Q36235578-EC92D78F-1830-4B15-A152-F2DF3C2CCC59Q37084012-EB3965E1-C8E8-428C-A21F-6BC6F9BFFB8AQ37156957-228A60DA-E837-40ED-BA7A-1F907A2CD758Q38005224-7BA8A77C-24DF-4D2F-8083-9D3FEBC9FA11Q38198108-FD4CE0E0-8FA0-49E7-9939-D56614ED97AEQ38469040-AE162FAC-1831-4B40-8DE4-73BEE4AE4CD1Q39416222-BA2534FE-2724-472B-BD97-9D6163EA5B1FQ42388707-E115E042-EE94-4442-8554-FA7E76487A23Q42749938-EB92A95C-C12C-4669-8814-E88CE4920689Q42866001-E1332D8C-0E48-4938-AE59-45079C80546BQ43142904-43F639A7-8A64-4D37-A005-2056E0AD0642Q43233198-D8CC006C-C965-42FE-AF7D-52379C5D936EQ44033728-73201276-3C3E-434B-8D50-975867507502Q45921089-220B1927-BBFE-4D3A-8B67-95B1E095FEC9Q45975360-F685E907-5F55-4D11-9734-68C76C6E1F4CQ48106921-4093C15F-CF08-48F7-802D-A481E689A00BQ48132839-9A8616FB-BB5A-463D-A0E2-017D7129F513Q48566880-CFD17B82-7E97-4A99-BDA0-172D7633A505Q48763785-8E86A715-5726-4519-9B5F-F1C683798428Q50586490-782AA0EB-BA00-4CCC-B6A5-27D1BF27DBF4Q51980534-2DD45A6C-2523-4E25-A55D-D16EFF067B07
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Psychiatric aspects of Parkinson's disease--an update.
@ast
Psychiatric aspects of Parkinson's disease--an update.
@en
type
label
Psychiatric aspects of Parkinson's disease--an update.
@ast
Psychiatric aspects of Parkinson's disease--an update.
@en
prefLabel
Psychiatric aspects of Parkinson's disease--an update.
@ast
Psychiatric aspects of Parkinson's disease--an update.
@en
P1433
P1476
Psychiatric aspects of Parkinson's disease--an update.
@en
P2888
P304
P356
10.1007/S00415-004-0483-3
P577
2004-07-01T00:00:00Z